Technical Analysis for MCRB - Seres Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Down |
| Historical MCRB trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| 20 DMA Support | Bullish | -1.53% | |
| 50 DMA Support | Bullish | -1.53% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -1.53% | |
| Spinning Top | Other | -1.53% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 50 DMA Support | about 16 hours ago |
| Outside Day | about 16 hours ago |
| Fell Below Previous Day's Low | about 16 hours ago |
| Down 2 % | about 17 hours ago |
| Down 1% | about 17 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/04/2021
Seres Therapeutics, Inc. Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has completed open label Phase Ib/2 clinical study for the prevention of further recurrences of Clostridium difficile infection (CDI). The company's product candidates in pre-clinical development comprise SER-262, an Ecobiotic microbiome therapeutic designed to be used following antibiotic treatment of primary CDI to prevent the initial recurrence of CDI; SER-287 to treat inflammatory bowel disease, including ulcerative colitis; and SER-155 to treat enteric pathogens, such as antibiotic-resistant bacteria. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Development Autoimmune Diseases Antibiotic Inflammatory Bowel Disease Ulcer Colitis Ulcerative Colitis Diarrhea Antimicrobial Resistance Digestive Diseases Clostridioides Difficile Cdi Clostridium Difficile Clostridium Difficile Infection
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 38.5 |
| 52 Week Low | 3.67 |
| Average Volume | 946,801 |
| 200-Day Moving Average | 24.38 |
| 50-Day Moving Average | 20.55 |
| 20-Day Moving Average | 20.89 |
| 10-Day Moving Average | 21.05 |
| Average True Range | 1.84 |
| ADX | 22.97 |
| +DI | 27.47 |
| -DI | 11.40 |
| Chandelier Exit (Long, 3 ATRs ) | 17.95 |
| Chandelier Exit (Short, 3 ATRs ) | 24.19 |
| Upper Bollinger Band | 22.26 |
| Lower Bollinger Band | 19.51 |
| Percent B (%b) | 0.42 |
| BandWidth | 13.15 |
| MACD Line | 0.11 |
| MACD Signal Line | 0.11 |
| MACD Histogram | -0.0082 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 24.14 | ||||
| Resistance 3 (R3) | 24.43 | 23.57 | 23.56 | ||
| Resistance 2 (R2) | 23.57 | 22.68 | 23.42 | 23.37 | |
| Resistance 1 (R1) | 22.11 | 22.13 | 21.68 | 21.82 | 23.17 |
| Pivot Point | 21.25 | 21.25 | 21.03 | 21.10 | 21.25 |
| Support 1 (S1) | 19.79 | 20.36 | 19.36 | 19.50 | 18.15 |
| Support 2 (S2) | 18.93 | 19.81 | 18.78 | 17.95 | |
| Support 3 (S3) | 17.47 | 18.93 | 17.76 | ||
| Support 4 (S4) | 17.18 |
